Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia
As of November 2023, there have been no new locally reported adverse events following immunisation (AEFIs) for COVID-19 vaccines, and the safety profiles of the vaccines have remained consistent. Therefore, the NPRA will cease publishing our periodic summary reports on COVID-19 vaccine safety and reported AEFIs. All previous summary reports remain available on the NPRA website as listed below.
Routine safety monitoring and surveillance of COVID-19 vaccines will continue, with timely communication of any significant emerging safety concerns. To receive the latest updates, join the NPRA Safety Information Mailing List by completing the subscription form.
The NPRA encourages anyone who suspects they have experienced a side effect linked to their COVID-19 vaccine to report it to the NPRA.
Laporan Ringkas Kesan Advers Susulan Imunisasi (AEFI) Vaksin COVID-19 di Malaysia (Data sehingga 30 Nov 2023)
Pengenalan
- Bagaimana NPRA mengumpul laporan kesan advers?
- Bagaimana NPRA memproses laporan AEFI dan memantau keselamatan vaksin COVID-19?
Jumlah Dos Vaksin COVID-19 Yang Diberikan
Kadar Pelaporan Kesan Advers
- Respon AEFI yang diterima melalui aplikasi MySejahtera
- Laporan AEFI yang diterima melalui Sistem Pelaporan NPRA
- Laporan AEFI di kalangan penerima dos penggalak vaksin COVID-19
- Pelaporan AEFI vaksin COVID-19 bagi golongan kanak-kanak berusia 5-11 tahun
Adverse Events of Special Interest (AESI)
Rumusan
- Manfaat pemberian vaksin COVID-19 melebihi risikonya
Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 30th Nov 2023)
Introduction
- How does NPRA collect adverse event reports?
- How does NPRA process AEFI reports and monitor safety of COVID-19 vaccines?
Total Doses of COVID-19 Vaccines Administered
Rate of Reported Adverse Events
- AEFI responses received via MySejahtera application
- AEFI reports received via NPRA Reporting System
- Booster doses
- COVID-19 vaccination in children aged 5 to 11 years
Adverse Events of Special Interest (AESI)
Summary
- Protective benefits of COVID-19 vaccination outweigh the potential risks
Laporan Ringkas Kesan Advers Susulan Imunisasi (AEFI) Vaksin COVID-19 di Malaysia (Data sehingga 30 Apr 2023)
Pengenalan
- Bagaimana NPRA mengumpul laporan kesan advers?
- Bagaimana NPRA memproses laporan AEFI dan memantau keselamatan vaksin COVID-19?
Jumlah Dos Vaksin COVID-19 Yang Diberikan
Kadar Pelaporan Kesan Advers
- Respon AEFI yang diterima melalui aplikasi MySejahtera
- Laporan AEFI yang diterima melalui Sistem Pelaporan NPRA
- Laporan AEFI di kalangan penerima dos penggalak vaksin COVID-19
- Pelaporan AEFI vaksin COVID-19 bagi golongan kanak-kanak berusia 5-11 tahun
Adverse Events of Special Interest (AESI)
Rumusan
- Manfaat pemberian vaksin COVID-19 melebihi risikonya
Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 30th Apr 2023)
Introduction
- How does NPRA collect adverse event reports?
- How does NPRA process AEFI reports and monitor safety of COVID-19 vaccines?
Total Doses of COVID-19 Vaccines Administered
Rate of Reported Adverse Events
- AEFI responses received via MySejahtera application
- AEFI reports received via NPRA Reporting System
- Booster doses
- COVID-19 vaccination in children aged 5 to 11 years
Adverse Events of Special Interest (AESI)
Summary
- Protective benefits of COVID-19 vaccination outweigh the potential risks
Laporan Ringkas Kesan Advers Susulan Imunisasi (AEFI) Vaksin COVID-19 di Malaysia (Data sehingga 31 Dis 2022)
Pengenalan
- Bagaimana NPRA mengumpul laporan kesan advers?
- Bagaimana NPRA memproses laporan AEFI dan memantau keselamatan vaksin COVID-19?
Jumlah Dos Vaksin COVID-19 Yang Diberikan
Kadar Pelaporan Kesan Advers
- Respon AEFI yang diterima melalui aplikasi MySejahtera
- Laporan AEFI yang diterima melalui Sistem Pelaporan NPRA
- Laporan AEFI di kalangan penerima dos penggalak vaksin COVID-19
- Pelaporan AEFI vaksin COVID-19 bagi golongan kanak-kanak berusia 5-11 tahun
Adverse Events of Special Interest (AESI)
Rumusan
- Manfaat pemberian vaksin COVID-19 melebihi risikonya
Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 31st Dec 2022)
Introduction
- How does NPRA collect adverse event reports?
- How does NPRA process AEFI reports and monitor safety of COVID-19 vaccines?
Total Doses of COVID-19 Vaccines Administered
Rate of Reported Adverse Events
- AEFI responses received via MySejahtera application
- AEFI reports received via NPRA Reporting System
- Booster doses
- COVID-19 vaccination in children aged 5 to 11 years
Adverse Events of Special Interest (AESI)
Summary
- Protective benefits of COVID-19 vaccination outweigh the potential risks
Laporan Ringkas Kesan Advers Susulan Imunisasi (AEFI) Vaksin COVID-19 di Malaysia (Data sehingga 20 Sep 2022)
Pengenalan
- Bagaimana NPRA mengumpul laporan kesan advers?
- Bagaimana NPRA memproses laporan AEFI dan memantau keselamatan vaksin COVID-19?
Jumlah Dos Vaksin COVID-19 Yang Diberikan
Kadar Pelaporan Kesan Advers
- Respon AEFI yang diterima melalui aplikasi MySejahtera
- Laporan AEFI yang diterima melalui Sistem Pelaporan NPRA
- Laporan AEFI di kalangan penerima dos penggalak vaksin COVID-19
- Pelaporan AEFI vaksin COVID-19 bagi golongan kanak-kanak berusia 5-11 tahun
Adverse Events of Special Interest (AESI)
Rumusan
- Manfaat pemberian vaksin COVID-19 melebihi risikonya
Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 20th Sept 2022)
Introduction
- How does NPRA collect adverse event reports?
- How does NPRA process AEFI reports and monitor safety of COVID-19 vaccines?
Total Doses of COVID-19 Vaccines Administered
Rate of Reported Adverse Events
- AEFI responses received via MySejahtera application
- AEFI reports received via NPRA Reporting System
- Booster doses
- COVID-19 vaccination in children aged 5 to 11 years
Adverse Events of Special Interest
Summary
- Protective benefits of COVID-19 vaccination outweigh the potential risks
Laporan Ringkas Kesan Advers Susulan Imunisasi (AEFI) Vaksin COVID-19 di Malaysia (Data sehingga 10 Jun 2022)
Pengenalan
- Bagaimana NPRA mengumpul laporan kesan advers?
- Bagaimana NPRA memproses laporan AEFI dan memantau keselamatan vaksin COVID-19?
Jumlah Dos Vaksin COVID-19 Yang Diberikan
Kadar Pelaporan Kesan Advers
- Respon AEFI yang diterima melalui aplikasi MySejahtera
- Laporan AEFI yang diterima melalui Sistem Pelaporan NPRA
- Laporan AEFI di kalangan penerima dos penggalak vaksin COVID-19
- Pelaporan AEFI vaksin COVID-19 bagi golongan remaja berusia 12-17 tahun
- Pelaporan AEFI vaksin COVID-19 bagi golongan kanak-kanak berusia 5-11 tahun
Adverse Events of Special Interest (AESI)
Rumusan
- Manfaat pemberian vaksin COVID-19 melebihi risikonya
Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 10th June 2022)
Introduction
- How does NPRA collect adverse event reports?
- How does NPRA process AEFI reports and monitor safety of COVID-19 vaccines?
Total Doses of COVID-19 Vaccines Administered
Rate of Reported Adverse Events
- AEFI responses received via MySejahtera application
- AEFI reports received via NPRA Reporting System
- Booster doses (PICK-B)
- COVID-19 vaccination in adolescents aged 12 to 17 years
- COVID-19 vaccination in children aged 5 to 11 years
Adverse Events of Special Interest
Summary
- Protective benefits of COVID-19 vaccination outweigh the potential risks
Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 11th March 2022)
Introduction
- How NPRA collects adverse event reports?
- How NPRA processes AEFI reports and monitors safety of COVID-19 vaccines?
Total Doses of COVID-19 Vaccines Administered
Rate of Reported Adverse Events
- AEFI responses received via MySejahtera application
- AEFI reports received via NPRA Reporting System
- Booster doses (PICK-B)
- COVID-19 vaccination in children aged 5 to 11 years (PICKids)
Adverse Events of Special Interest
Summary
- Protective benefits of COVID-19 vaccination outweigh the potential risks
Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 31st December 2021)
Introduction
- How NPRA collects adverse event reports?
- How NPRA processes AEFI reports and monitors safety of COVID-19 vaccines?
Total Doses of COVID-19 Vaccines Administered
Rate of Reported Adverse Events
- AEFI responses received via MySejahtera application
- AEFI reports received via NPRA Reporting System
- COVID-19 vaccination in the age of 12 to 17 years
- Booster doses
Adverse Events of Special Interest
Summary
- Protective benefits of COVID-19 vaccination outweigh the potential risks
Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 29th October 2021)
Introduction
- How NPRA collects adverse event reports?
- How NPRA processes AEFI reports and monitors safety of COVID-19 vaccines?
Total Doses of COVID-19 Vaccines Administered
Rate of Reported Adverse Events
- AEFI responses received via MySejahtera application
- AEFI reports received via NPRA Reporting System
Summary
- Protective benefits of COVID-19 vaccination outweigh the potential risks
